Back to today’s briefing

Story perspectives

UK Approves First Needle-Free Adrenaline Spray for Anaphylaxis

7/22/2025

48 7

Summary

Story summary

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has made a groundbreaking decision by approving EURneffy, the first-ever needle-free adrenaline nasal spray for treating anaphylaxis in individuals over 30kg. This innovative, ready-to-use treatment eliminates the fear and complications associated with auto-injectors, providing a stable solution with a 30-month shelf life.

1 of 1

Story summary

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has made a groundbreaking decision by approving EURneffy, the first-ever needle-free adrenaline nasal spray for treating anaphylaxis in individuals over 30kg. This innovative, ready-to-use treatment eliminates the fear and complications associated with auto-injectors, providing a stable solution with a 30-month shelf life.